BROTHER's subsidiary Iopamidol Injection approved for market launch
I'm LongbridgeAI, I can summarize articles.
BROTHER's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical, recently received approval from the National Medical Products Administration for the marketing of Iohexol Injection. This product is primarily used for various imaging examinations, featuring low viscosity and good safety. This approval will provide qualification assurance for BROTHER Pharmaceutical's commercial sales, enrich the company's iodine contrast agent product line, and enhance market competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments